FDA: Generic Drugs Can Help Slash Prices
Posted on: Tuesday, 4 April 2006, 12:00 CDT
WASHINGTON - Prescription drug prices soften dramatically even with moderate competition, the Food and Drug Administration said Tuesday in an analysis that shows the arrival in the marketplace of just two generic versions of a brand-name medicine can nearly halve the price consumers pay.
When a brand-name drug faces just one generic competitor, that challenger typically sells for 94 percent of the cost of its branded rival. More competition quickly widens that discount: Once a second generic manufacturer appears, the average price of a generic drug drops to just 52 percent of the brand-name version's cost per dose, according to the analysis posted on the FDA Web site.
Prices continue to tumble, albeit more slowly but almost without exception, as more manufacturers join the market, the analysis shows. By the time nine manufacturers are producing generic versions of a drug, their products typically sell for just 20 percent of the price of the brand-name medicine, according to the federal analysis of 1999-2004 retail sales data on single-ingredient drug products collected by IMS Health Inc.
Release of the analysis comes amid ongoing criticism that the FDA is slow to approve generic versions of brand-name pharmaceuticals. The agency has a backlog of roughly 800 generic drug applications.
---
On the Net:
Food and Drug Administration: http://www.fda.gov/
Source: Associated Press/AP Online
Related Articles
- Stopain(R) Named a 'Demand Brand' by Mass Market Retailers Magazine
- Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
- Crystallize Your Business Decisions With Drug Approval Trends at the FDA and EMEA Report
- Infinity and MedImmune Report Generic Name Approval for Cancer Drug
- To Control Japan's Total Health Care Expenditures Devoted to Drugs, the Government Sets the Reimbursement Prices for New Branded Drugs
- The Most Efficient Way to Get Your Food and Drug Products to Market Within FDA Regulations
- Peregrine Pharmaceuticals Transitions Tarvacin Name to Official Generic Name Bavituximab
- USAN and WHO Approve Generic Name Bremelanotide for PT-141, First in a New Class of Experimental Treatments for Sexual Dysfunction
- ADHD Drug May Spur Suicidal Thoughts, FDA Warns
- American Consumers Suffer As More New Drugs Debut in U.S., Analysis Shows
 |
 |
User Comments (0)
RSS Feeds